曲恩汀治疗肥厚型心肌病随机试验的原理与设计
TEMPEST 试验是一项多中心、双盲、平行组、1:1 随机、安慰剂对照的 II 期试验,旨在评估曲恩汀在肥厚型心肌病(HCM)患者中的疗效与作用机制。研究纳入符合欧洲心脏病学会指南诊断且 NYHA I-III 级的 HCM 患者,随机接受曲恩汀或安慰剂治疗 52 周,主要结局为心血管磁共振测量的左心室质量指数变化。
要点
- 曲恩汀是高度选择性铜 II 螯合剂,临床前及糖尿病研究提示其可减少左心室肥厚和纤维化。
- TEMPEST 主要结局为 52 周时心血管磁共振测量的左心室质量指数变化。
- 次要结局包括运动能力、心律失常负荷、心肌细胞损伤、左室及心房功能、左室流出道压差。
核心结论
- TEMPEST 试验将确定曲恩汀在 HCM 患者中的疗效与作用机制。
研究设计与样本
- TEMPEST 为多中心、双盲、平行组、1:1 随机、安慰剂对照的 II 期试验。
- 纳入符合欧洲心脏病学会指南诊断且 NYHA I-III 级的 HCM 患者,随机接受曲恩汀或匹配安慰剂治疗 52 周。
主要发现
- 临床前及糖尿病临床研究中,曲恩汀与左心室肥厚和纤维化减少、线粒体功能及能量代谢改善相关。
- 开放标签研究显示曲恩汀与 HCM 患者心脏结构和功能改善相关。
关键数值与推荐
- 主要结局为心血管磁共振测量的左心室质量指数(以体表面积标化)变化。
- 次要疗效目标包括运动能力、心律失常负荷、心肌细胞损伤、左室及心房功能、左室流出道压差。
- 机制目标将确定效应是否由细胞或细胞外质量消退及心肌能量学改善介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of antioxidants. Trientine is a highly selective copper II chelator. In preclinical and clinical studies in diabetes, trientine is associated with reduced LVH and fibrosis, and improved mitochondrial function and energy metabolism. Trientine was associated with improvements in cardiac structure and function in an open-label study in patients with HCM. METHODS: The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) trial is a multicentre, double-blind, parallel group, 1:1 randomised, placebo-controlled phase II trial designed to evaluate the efficacy and mechanism of action of trientine in patients with HCM. Patients with a diagnosis of HCM according to the European Society of Cardiology Guidelines and in New York Heart Association classes I-III are randomised to trientine or matching placebo for 52 weeks. Primary outcome is change in left ventricular (LV) mass indexed to body surface area, measured using cardiovascular magnetic resonance. Secondary efficacy objectives will determine whether trientine improves exercise capacity, reduces arrhythmia burden, reduces cardiomyocyte injury, improves LV and atrial function, and reduces LV outflow tract gradient. Mechanistic objectives will determine whether the effects are mediated by cellular or extracellular mass regression and improved myocardial energetics. CONCLUSION: TEMPEST will determine the efficacy and mechanism of action of trientine in patients with HCM. TRIAL REGISTRATION NUMBERS: NCT04706429 and ISRCTN57145331.
引用
- Farrant J, Dodd S, Vaughan C, et al. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy. Heart. 2023. PMID: 37137675. doi:10.1136/heartjnl-2022-322271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。